-
1.发明授权Modified TNF-alpha molecules, DNA encoding such and vaccines comprising such modified TNF-alpha and DNA 失效修饰的TNF-α分子，编码这样的DNA和包含这种修饰的TNF-α和DNA的疫苗公开(公告)号：US07118750B1
公开(公告)日：2006-10-10
申请号：US09060294
申请日：1998-04-15
CPC分类号： C07K14/525 , A61K38/00 , A61K39/00 , C07K19/00 , C07K2319/00 , Y10S930/144
摘要： A modified human TNFα molecule is capable of raising neutralizing antibodies towards unmodified human TNFα following administration of the modified TNFα to a human host, wherein one or more peptide fragments of the human TNFα molecule has been substituted by one or more peptides containing immunodominant T cell epitopes or a truncated form of the molecule containing the immunodominant epitope and one or both flanking regions of the human TNFα-molecule containing at least one TNFα B cell epitope, wherein the substitution introduces a substantial change in the amino acid sequence of any one of the strands of the front β-sheet, in any one of the connecting loops, or in any one of the B′, I, or D strands of the back β-sheet.
摘要翻译： 在将修饰的TNFα施用于人宿主后，经修饰的人TNFα分子能够提供针对未修饰的人TNFα的中和抗体，其中人TNFα分子的一个或多个肽片段已被含有免疫优势T细胞表位的一种或多种肽取代 或包含免疫显性表位和含有至少一种TNFαb细胞表位的人TNFα分子的一个或两个侧翼区域的分子的截短形式，其中所述取代引入任何一条链的氨基酸序列的显着变化 在任何一个连接环中，或在背面β片中的任何一个B'，I或D链中的前β片。
-
公开(公告)号：US09567567B2
公开(公告)日：2017-02-14
申请号：US13816359
申请日：2011-08-11
IPC分类号： C12N5/0784 , C12N5/0783 , A61K35/15 , A61K35/17 , A61K39/00 , A61K35/12
CPC分类号： C12N5/0639 , A61K35/15 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C12N5/0638 , C12N2500/90 , C12N2501/02 , C12N2501/2301 , C12N2501/2306 , C12N2501/25 , C12N2501/91 , C12N2506/115 , C12N2533/70 , C12N2533/90
摘要： The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.
摘要翻译： 本发明涉及用于制备树突状细胞的组合物和方法，特别涉及用于产生免疫能力的未成熟树突状细胞的组合物和方法。 我们描述了通过培养单核细胞产生树突状细胞的方法，其特征在于以下至少之一：用至少一种以下的至少一种预处理组织培养表面：基本上无血浆和无血清的预处理培养基， 包含肝素的处理培养基和包含蛋白质溶液的预处理培养基; 使用基本上无血浆和无血清的吸附介质中的至少一种吸附单核细胞; 使用基本上无血浆和无血清的培养基培养单核细胞。 我们还描述了包括牙髓细胞和牙髓细胞的用途的组合物。
-
公开(公告)号：US07135181B2
公开(公告)日：2006-11-14
申请号：US09785215
申请日：2001-02-20
CPC分类号： A61K39/385 , A61K38/00 , A61K38/1709 , A61K39/0007 , A61K47/646 , A61K2039/53 , A61K2039/6037 , A61K2039/6087 , A61K2039/64 , C07K14/4711 , C07K2319/00 , G01N33/6896 , G01N2333/4709 , G01N2500/04
摘要： A method for in vivo down-regulation of amyloid protein in an animal, including a human being, the method comprising effecting presentation to the animal's immune system of an immunogenically effective amount of at least one amyloidogenic polypeptide or subsequence thereof which has been formulated so that immunization of the animal with the amyloidgenic polypeptide or subsequence thereof induces production of antibodies against the amyloidogenic polypeptide, and/or at least one analogue of the amyloidogenic polypeptide wherein is introduced at least one modification in the amino acid sequence of the amyloidogenic polypeptide which has as a result the immunization of the animal with the analogue induces production of antibodies against the amyloidogenic polypeptide.
摘要翻译： 一种用于动物体内下调淀粉样蛋白的方法，包括人，所述方法包括向动物的免疫系统呈递免疫有效量的至少一种淀粉样变性多肽或其子序列，其被配制成使得 用淀粉样蛋白生成多肽或其子序列免疫动物诱导针对淀粉样变性多肽和/或淀粉样变性多肽的至少一种类似物的抗体的产生，其中引入淀粉样变性多肽的氨基酸序列中的至少一个修饰，其具有如 结果，用该类似物的动物的免疫诱导产生针对淀粉样变性多肽的抗体。
-
公开(公告)号：US20130216584A1
公开(公告)日：2013-08-22
申请号：US13816359
申请日：2011-08-11
IPC分类号： C12N5/0784 , C12N5/0783 , A61K35/14
CPC分类号： C12N5/0639 , A61K35/15 , A61K35/17 , A61K39/0011 , A61K2035/124 , A61K2039/5154 , A61K2039/5158 , C12N5/0638 , C12N2500/90 , C12N2501/02 , C12N2501/2301 , C12N2501/2306 , C12N2501/25 , C12N2501/91 , C12N2506/115 , C12N2533/70 , C12N2533/90
摘要： The present invention relates to compositions and methods for producing dendritic cells and particularly to compositions and methods for producing immature dendritic cells that are immunocompetent. We describe a method of producing dendritic cells by cultivation of monocytes, characterised by at least one of: pre-treatment of a tissue culture surface with at least one of: a substantially plasma-free and serum-free pre-treatment medium, a pre-treatment medium comprising heparin, and a pre-treatment medium comprising a protein solution; adsorption of monocytes using at least one of: a substantially plasma-free and serum-free adsorption medium; cultivation of monocytes using a substantially plasma-free and serum-free cultivation medium. We also describe compositions including the dentritic cells and uses of the dentritic cells.
摘要翻译： 本发明涉及用于制备树突状细胞的组合物和方法，特别涉及用于产生免疫能力的未成熟树突状细胞的组合物和方法。 我们描述了通过培养单核细胞产生树突状细胞的方法，其特征在于以下至少之一：用至少一种以下的至少一种预处理组织培养表面：基本上无血浆和无血清的预处理培养基， 包含肝素的处理培养基和包含蛋白质溶液的预处理培养基; 使用基本上无血浆和无血清的吸附介质中的至少一种吸附单核细胞; 使用基本上无血浆和无血清的培养基培养单核细胞。 我们还描述了包括牙髓细胞和牙髓细胞的用途的组合物。
-
公开(公告)号：US20090092579A1
公开(公告)日：2009-04-09
申请号：US12108478
申请日：2008-04-23
IPC分类号： A61K38/20 , A61K39/00 , C07K14/00 , C12N15/11 , C12N15/00 , C12N1/21 , A61K38/21 , C07K16/18 , C12N1/19 , C12N1/10 , C12N5/06 , A61K38/16 , C12N15/87
CPC分类号： A61K39/385 , A61K38/00 , A61K38/1709 , A61K39/0007 , A61K47/646 , A61K2039/53 , A61K2039/6037 , A61K2039/6087 , A61K2039/64 , C07K14/4711 , C07K2319/00 , G01N33/6896 , G01N2333/4709 , G01N2500/04
摘要： Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of Aβ's B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
摘要翻译： 公开了用于对抗以沉淀淀粉样蛋白为特征的疾病的新方法。 所述方法通常依赖于抗淀粉样变蛋白（有助于形成淀粉样蛋白的蛋白质）如β淀粉样蛋白（Abeta）的免疫。 免疫优选通过施用自体淀粉样蛋白多肽的类似物来实现，所述类似物能够诱导针对自体淀粉样蛋白多肽的抗体产生。 作为免疫原特别优选的是通过引入一个或几个外来的免疫显性和混杂的T细胞表位而修饰的自体Abeta，同时基本上保留了大部分的Abeta的B细胞表位。 还公开了针对淀粉样变性多肽的核酸接种和使用活疫苗的疫苗接种以及可用于疫苗接种的方法和装置。 这样的方法和手段包括用于鉴定淀粉样蛋白形成蛋白质的有用的免疫原性类似物的方法，用于制备类似物和药物制剂的方法，以及核酸片段，载体，转化细胞，多肽和药物制剂。
-
公开(公告)号：US20090311281A1
公开(公告)日：2009-12-17
申请号：US12360962
申请日：2009-01-28
IPC分类号： A61K39/00
CPC分类号： G01N33/6896 , A61K38/00 , A61K38/1709 , A61K38/19 , A61K39/00 , A61K39/0007 , A61K39/385 , A61K47/646 , A61K2039/53 , A61K2039/6037 , A61K2039/6087 , A61K2039/64 , C07K14/4711 , C07K2319/00 , G01N2333/4709 , G01N2500/04 , Y02A50/412 , A61K2300/00
摘要： Disclosed are novel methods for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloidogenic proteins (proteins contributing to formation of amyloid) such as beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous amyloidogenic polypeptides, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes while substantially preserving the majority of Aβ's B-cell epitopes. Also disclosed are nucleic acid vaccination against amyloidogenic polypeptides and vaccination using live vaccines as well as methods and means useful for the vaccination. Such methods and means include methods for identification of useful immunogenic analogues of the amyloidogenic proteins, methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
-
公开(公告)号：US08871212B2
公开(公告)日：2014-10-28
申请号：US12339841
申请日：2008-12-19
申请人： Peter Birk Rasmussen , Martin Roland Jensen , Klaus Gregorius Nielsen , Peter Koefoed , Florence Dal Degan
发明人： Peter Birk Rasmussen , Martin Roland Jensen , Klaus Gregorius Nielsen , Peter Koefoed , Florence Dal Degan
IPC分类号： A61K39/00 , A61K39/385 , A61K39/08 , A01K67/027 , C07K14/47
CPC分类号： A61K39/0007 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0312 , A61K39/385 , A61K45/06 , A61K2039/53 , A61K2039/6037 , A61K2039/6068 , A61K2039/6087 , A61K2039/6093 , A61K2039/64 , C07K14/4711 , Y02A50/412
摘要： Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogs of autologous APP or Aβ, said analogs being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogs and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
摘要翻译： 公开了用于防治以沉淀淀粉样蛋白为特征的疾病的新颖方法和组合物。 所述方法通常依赖于针对淀粉样前体蛋白（APP）或β淀粉样蛋白（A＆bgr）的免疫。 免疫优选通过施用自体APP或A＆bgr的类似物来实现;所述类似物能够诱导针对自体淀粉样蛋白形成多肽的抗体产生。 特别优选作为免疫原是自体A＆bgr; 其通过引入一种或几种外来的免疫显性和混杂的T细胞表位而被修饰。 这些方法和手段包括制备类似物和药物制剂以及核酸片段，载体，转化细胞，多肽和药物制剂的方法。
-
公开(公告)号：US20100047262A1
公开(公告)日：2010-02-25
申请号：US12339841
申请日：2008-12-19
申请人： Peter Birk Rasmussen , Martin Roland Jensen , Klaus Gregorius Nielsen , Peter Koefoed , Florence Dal Degan
发明人： Peter Birk Rasmussen , Martin Roland Jensen , Klaus Gregorius Nielsen , Peter Koefoed , Florence Dal Degan
CPC分类号： A61K39/0007 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0312 , A61K39/385 , A61K45/06 , A61K2039/53 , A61K2039/6037 , A61K2039/6068 , A61K2039/6087 , A61K2039/6093 , A61K2039/64 , C07K14/4711 , Y02A50/412
摘要： Disclosed are novel methods and compositions for combating diseases characterized by deposition of amyloid. The methods generally rely on immunization against amyloid precursor protein (APP) or beta amyloid (Aβ). Immunization is preferably effected by administration of analogues of autologous APP or Aβ, said analogues being capable of inducing antibody production against the autologous amyloidogenic polypeptides. Especially preferred as an immunogen is autologous Aβ which has been modified by introduction of one single or a few foreign, immunodominant and promiscuous T-cell epitopes. Such methods and means include methods for the preparation of analogues and pharmaceutical formulations, as well as nucleic acid fragments, vectors, transformed cells, polypeptides and pharmaceutical formulations.
摘要翻译： 公开了用于防治以沉淀淀粉样蛋白为特征的疾病的新颖方法和组合物。 所述方法通常依赖于针对淀粉样前体蛋白（APP）或β淀粉样蛋白（A＆bgr）的免疫。 免疫优选通过施用自体APP或A＆bgr的类似物来实现;所述类似物能够诱导针对自体淀粉样变性多肽的抗体产生。 特别优选作为免疫原是自体A＆bgr; 其通过引入一种或几种外来的免疫显性和混杂的T细胞表位而被修饰。 这些方法和手段包括制备类似物和药物制剂以及核酸片段，载体，转化细胞，多肽和药物制剂的方法。
-
-
-
-
-
-
-
搜索结果
8 条记录 (耗时 0.029 秒)
